nan
Autologous Hematopoietic Stem Cell Gene Therapy Market Forecast: What Market Value Is Expected By 2030?
The market size for reversible inhibitors of monoamine (RIMA) antidepressants has demonstrated robust growth in recent years. It is forecasted to expand from $5.67 billion in 2025 to $5.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. The historical growth of this market can be attributed to the increasing prevalence of depression and anxiety disorders, greater awareness regarding mental health treatment, wider adoption of antidepressant pharmacotherapy, the development of selective monoamine oxidase inhibitors, and advancements in psychiatric diagnosis and screening.
The reversible inhibitors of monoamine (RIMA) antidepressants market size is projected to experience strong growth in the coming years. It is expected to reach $7.49 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.8%. This expansion during the forecast period can be attributed to several factors, including the advancement of precision medicine for mental health disorders, the integration of digital therapeutics with pharmacological treatment, a rising demand for safer reversible antidepressant therapies, the broader expansion of telepsychiatry services, and ongoing advancements in neurobiology and neurotransmitter research. Significant trends anticipated in this period involve the adoption of personalized psychiatry and precision psychopharmacology, the integration of digital mental health with antidepressant therapy monitoring, biomarker-driven neurochemical treatment optimization, the wider implementation of outpatient psychiatric care models, and an increased focus on the safety of drugs that target reversible enzymes.
Download A Free Sample Report For Comprehensive Market Insights:
Reversible Inhibitors Of Monoamine (RIMA) Antidepressants Market Growth Factors Supporting Long-Term Expansion
The expanding occurrence of depression and anxiety conditions is anticipated to boost the reversible inhibitors of monoamine (RIMA) antidepressants market moving forward. The prevalence of these mental health conditions denotes the proportion of individuals within a specific population affected at a particular time or over a defined duration. This increase is primarily due to a combination of rising social and economic pressures. RIMA treatments address this growing prevalence by offering antidepressant options that are safer and more tolerable, eliminating the stringent dietary restrictions associated with older therapies. For instance, in May 2024, the American Psychiatric Association, a U.S.-based non-profit, reported in its 2024 annual mental health poll a consistent increase in anxiety among U.S. adults, with 43% of participants stating they felt more anxious in 2024 compared to the previous year, an increase from 37% in 2023 and 32% in 2022. Consequently, the rising occurrence of depression and anxiety disorders is propelling the growth of the reversible inhibitors of monoamine (RIMA) antidepressants market. Increased spending on healthcare is set to stimulate the growth of the reversible inhibitors of monoamine (RIMA) antidepressants market in the future. Healthcare expenditure encompasses the total funds allocated to healthcare goods and services, including medical treatments, hospital care, medications, and mental health services. This rise in spending is largely a result of increased investments in healthcare infrastructure and greater public awareness of psychiatric disorders. Elevated healthcare expenditure facilitates the adoption of reversible inhibitors of monoamine (RIMA) antidepressants by enhancing access to advanced mental health treatments, improving psychiatric care services, and increasing investment in effective antidepressant therapies. For example, in April 2025, the American Medical Association, a U.S.-based professional organization representing physicians and medical students, indicated that U.S. healthcare spending expanded by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, a notable increase from the 4.6% growth rate observed in 2022. Therefore, rising healthcare expenditure is a key driver for the growth of the reversible inhibitors of monoamine (RIMA) antidepressants market.
#Autologous Hematopoietic Stem Cell Gene Therapy Market Segment Landscape And Growth Potential
The reversible inhibitors of monoamine (rima) antidepressants market covered in this report is segmented –
1) By Type: Selective Reversible Inhibitors Of Monoamine Oxidase A; Non Selective Reversible Inhibitors Of Monoamine Oxidase A
2) By Indication: Dysthymia; Major Depressive Disorder; Anxiety Disorders; Social Phobia; Other Indications
3) By Patient Demographics: Adolescent; Adult; Geriatric
4) By End User: Hospitals And Clinics; Research And Academic Institutions
Subsegments:
1) By Selective Reversible Inhibitors Of Monoamine Oxidase A: Pirlindole; Moclobemide; Metralindole; Brofaromine
2) By Non Selective Reversible Inhibitors Of Monoamine Oxidase A: Multimodal Action Monoamine Oxidase Inhibitors; Dual Reversible Inhibitors Of Monoamine Oxidase A And B; Natural Reversible Inhibitors Of Monoamine Oxidase A; Investigational Reversible Inhibitors Of Monoamine Oxidase A Compounds
Reversible Inhibitors Of Monoamine (RIMA) Antidepressants Market Competitive Landscape And Leading Companies
Major companies operating in the reversible inhibitors of monoamine (rima) antidepressants market are AbbVie Inc.; Roche Holding AG; Viatris Inc.; H. Lundbeck A/S; Teva Pharmaceutical Industries Ltd.; Bausch Health Companies Inc.; Sun Pharmaceutical Industries Limited; Cipla Limited; Torrent Pharmaceuticals Ltd.; Intas Pharmaceuticals Limited; Apotex Inc.; Alembic Pharmaceuticals Limited; Lunan Pharmaceutical Group Corporation; Micro Labs Limited; Fabre-Kramer Pharmaceuticals Inc.
Access The Complete Reversible Inhibitors Of Monoamine (RIMA) Antidepressants Market Report:
Reversible Inhibitors Of Monoamine (RIMA) Antidepressants Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the reversible inhibitors of monoamine (RIMA) antidepressants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the reversible inhibitors of monoamine (RIMA) antidepressants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.